Delayed Severe Drug Induced Cholestasis After Anabolic Steroids Exposure
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Introduction
Anabolic steroids have become renowned as an
enhancement tool for athletic performance and muscle
development (1). One modification of testosterone is
through alkylation of the C-17 position to allow for oral
administration and that formula has been implicated in
cases of certain liver injuries that are less common in
esterified testosterones. These modified formulations
include products such as danazol, methyltestosterone and
stanazol (2). Testosterone therapy has been linked to
distinctive form of acute cholestasis that generally arises
within 1 to 4 months of therapy initiation but may be
delayed to as long as 6 to 24 months (3). We are presenting
a unique case where acute cholestasis occurred five weeks
after discontinuation of Stanazol use of one-week.

Case report
A 20-year-old African American male without significant
past medical history presented to the emergency
department with jaundice, mild nausea, and generalized
pruritis for four days. The patient stated that he had several
episodes of non-bilious vomiting during this time. All his
symptoms have been progressive and reports no prior
incidence.
On social history, patient denied any illicit drug use or
sexually transmitted infections but admitted to selfinitiation of oral stanozolol 40 mg daily. The patient used
this anabolic steroid for 7 days 5 weeks prior to his
symptoms developing. He denied any other prescription
drug use or tobacco use. He admitted to occasional alcohol
use that did not exceed 1-2 beers a week.
Family history was negative for any liver disease
including hepatitis, jaundice, cirrhosis, or malignancy.
Physical exam showed normal vital signs, mildly
jaundiced well-nourished male with scleral icterus. His
abdominal exam was benign without any
hepatosplenomegaly; otherwise normal physical
exam.

Figure 1, 2, and 3

Hospital Course
Initial complete blood count and basic metabolic panel were
unremarkable. Liver function profile with ALT of 44 IU/L, AST of 72 IU/L,
Alk Phos of 266 IU/L, T. Bili of 21.4 mg/Dl, and INR of 1.2. The rest of his
labs were unremarkable except for mildly elevated ferritin levels at 669
ng/ML.
Initial workup including hepatitis A, B and C, HSV 1&2, CMV, HIV, EBV,
Wilson’s, hereditary hemochromatosis and autoimmune disorders were
all negative. Imaging of the liver, gallbladder and the biliary system did
not reveal any pathology (Figures 1, 2, and 3). Bilirubin was trended and
continued to rise on the subsequent days, thus a CT-guided liver biopsy
was performed. Slides were prepared and examined under the
microscope using H&E stain and showed moderate to marked
hepatocanalicular cholestasis with minimal centrilobular and
hepatocellular injury (Figure 4, 5).

That pathology finding in the light of the clinical presentation was
strongly suggestive of drug induced cholestasis. The patient was
discharged with cholestyramine and Zofran for symptomatic
management. Follow up as an outpatient was scheduled with our
resident clinic and bilirubin at discharge was 22.1 mg/dl. After twoweeks, total bilirubin trended up to 39 mg/dl and the patient was
started on ursodeoxycholic acid. At 4 weeks after discharge the
total bilirubin started to decline to 13 mg/dl with resolution of his
symptoms.

Discussion
• The use of anabolic steroids has been linked to multiple liver
pathologies including bland cholestasis, peliosis hepatis, hepatic
adenoma, hepatocellular carcinoma and nodular regenerative
hyperplasia. Most pathologies happen with long term use of
these medications (4). However cholestasis can happen after a
short course of anabolic steroids as seen in our case.
• Oral anabolic steroids are more commonly associated with acute
cholestasis due to the C-17 alkylation.
• Although cholestasis are usually reversable with stopping
therapy, full recovery is often delayed. In addition, fatalities
have been reported, usually due to marked cholestasis
complicated by malnutrition, renal failure, and associated
opportunistic infections (5).
• A study of men who regularly attended gyms in London in 2000
found that 15.2% of the 792 men surveyed had used anabolic
steroids in the preceding year (6). This data highlights the
prevalence of anabolic steroids and the importance of asking
about recent and remote anabolic steroids use in younger males
with abnormal liver functions to prevent progressive liver injury.
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•Figure 4. CT-guided core biopsy of liver shows
moderate to marked hepatocanalicular cholestasis
with centrizonal distribution and associated bile plugs
(hematoxylin-eosin, original magnification 400X).

•Figure 5. CT-guided core biopsy of liver shows
minimal hepatocellular injury with few perivenular
hepatocytes with balloon degeneration and minimal
to mild centrilobular inflammation (hematoxylineosin, original magnification 400X).
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